Consolidated balance sheet
(in CHF 1 000)
|
|
|
Notes |
|
30.09.2021 |
|
31.12.2020 |
|
Current assets |
|
|
|
|
|
|
|
Cash and cash equivalents |
|
|
|
1 775 |
|
6 816 |
|
Receivables from brokers |
|
|
|
– |
|
1 521 |
|
Securities |
|
4 |
|
4 093 103 |
|
3 954 659 |
|
Other assets |
|
|
|
112 |
|
139 |
|
|
|
|
|
4 094 990 |
|
3 963 135 |
|
Total assets |
|
|
|
4 094 990 |
|
3 963 135 |
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
Short-term borrowings from banks |
|
5 |
|
248 000 |
|
63 000 |
|
Payables to brokers |
|
|
|
7 779 |
|
6 576 |
|
Other short-term liabilities |
|
|
|
5 814 |
|
5 709 |
|
Tax liabilities |
|
|
|
162 |
|
303 |
|
|
|
|
|
261 755 |
|
75 588 |
|
Total liabilities |
|
|
|
261 755 |
|
75 588 |
|
|
|
|
|
|
|
|
|
Shareholders' equity |
|
|
|
|
|
|
|
Share capital |
|
6 |
|
11 080 |
|
11 080 |
|
Treasury shares |
|
6 |
|
(5 368) |
|
(8 241) |
|
Retained earnings |
|
|
|
3 827 523 |
|
3 884 708 |
|
|
|
|
|
3 833 235 |
|
3 887 547 |
|
Total liabilities and shareholders' equity |
|
|
|
4 094 990 |
|
3 963 135 |
|
|
|
|
|
|
|
|
|
Net asset value per share in CHF |
|
|
|
69.25 |
|
70.30 |
The notes are an integral part of the condensed consolidated interim financial statements.
The consolidated financial statements were approved by the Board of Directors of BB Biotech AG on October 19, 2021.